Systemic inflammatory biomarkers and co-morbidities of chronic obstructive pulmonary disease.
about
Managing comorbidities in COPDRelationships of MMP-9 and TIMP-1 proteins with chronic obstructive pulmonary disease risk: A systematic review and meta-analysisCo-morbidities are the key nominators of the health related quality of life in mild and moderate COPD.Airway inflammation in Japanese COPD patients compared with smoking and nonsmoking controlsDepletion of bone marrow CCSP-expressing cells delays airway regeneration.Fracture prevention in COPD patients; a clinical 5-step approachAnti-inflammatory effects of salmeterol/fluticasone propionate 50/250 mcg combination therapy in Japanese patients with chronic obstructive pulmonary disease.Serum Metabolite Biomarkers Discriminate Healthy Smokers from COPD SmokersIncreased serum TRAIL and DR5 levels correlated with lung function and inflammation in stable COPD patients.Responsiveness of blood and sputum inflammatory cells in Japanese COPD patients, non-COPD smoking controls, and non-COPD nonsmoking controls.Dietary inflammatory index and risk of lung cancer and other respiratory conditions among heavy smokers in the COSMOS screening study.Statins and morbidity and mortality in COPD in the COMIC study: a prospective COPD cohort study.Usefulness of neutrophil to lymphocyte ratio in patients with chronic obstructive pulmonary disease: a prospective observational study.Airflow limitation as a risk factor for low bone mineral density and hip fracture.A repeat-dose thorough QT study of inhaled fluticasone furoate/vilanterol combination in healthy subjectsThe recent advances of phenotypes in acute exacerbations of COPD.Chronic obstructive pulmonary disease (COPD): evaluation from clinical, immunological and bacterial pathogenesis perspectives.Bacteria in COPD; their potential role and treatment.Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases.Association of plasma adipokines with chronic obstructive pulmonary disease severity and progression.Diabetes risks and outcomes in chronic obstructive pulmonary disease patients: Two nationwide population-based retrospective cohort studies.Circulating Inflammation Markers, Risk of Lung Cancer, and Utility for Risk Stratification.Systemic tentacles of chronic obstructive pulmonary disease: do we need to account for renal damage?Evaluating the role of inflammation in chronic airways disease: the ERICA study.Association of Serum Galectin-3 with the Acute Exacerbation of Chronic Obstructive Pulmonary Disease.The clinical implication of serum cyclophilin A in patients with chronic obstructive pulmonary disease.Rosuvastatin treatment in stable chronic obstructive pulmonary disease (RODEO): a randomized controlled trial.Systemic redox imbalance in stable chronic obstructive pulmonary disease.Serum Cystatin C as an Inflammatory Marker in Exacerbated and Convalescent COPD Patients.Status of coexisting chronic obstructive pulmonary disease and its clinicopathological features in patients undergoing lung cancer surgery: a cross-sectional study of 3,006 cases.Co-Morbidities as Predictors of Airflow Limitation among Smokers in England.
P2860
Q27005858-6A725D43-AC4E-43F9-81F8-48131384218EQ28076457-FDEB67B6-9DEB-4769-B88E-EC3BB080F361Q34500895-82248DB4-7EB2-4C50-939E-F7F9BB5BE402Q35042664-709E0AE3-8049-4101-B957-AD4342578189Q35153100-5DD8496E-D0AA-435D-8162-DB17583A5E43Q35158568-4C3961B1-C474-4460-9A25-4A3F50550DE0Q35531955-384F29C5-9629-4F89-BD4A-C0E93D1F9B35Q35870656-AC00ADE1-567E-45E6-956E-42CF321A2662Q36277943-B74CCA07-AF88-4B16-9119-E81EDCA786FBQ36585746-F4E18534-A75B-4DFD-BBDB-0F5DF4DC121EQ36839661-18971967-D1FA-4A3F-AB53-2AC2AE2C5D66Q37063674-C6A850F7-930B-44C6-9099-AB6872210397Q37242596-0715B60C-F35C-4B59-B3FA-2F6C0FB4B3BDQ37335082-3AE9FD05-2223-4E6D-A0CB-BD00048B3F84Q37635200-93A01E6E-F760-4DB2-837B-1075F4DD3E43Q37732387-8EAB102E-B925-44DE-A5EB-92148D24D4C5Q38192501-A3F6461E-75B9-4A25-B206-C4F6D75A0EE0Q38846409-1E9CFE0C-3777-4961-B6E5-E8AD6115BA31Q38871993-ACE525DD-7EE7-4F12-BD89-CC9EA0F364B3Q40902162-341DF73B-6C69-42A6-8C76-DCEDBE9F0B87Q41432972-BDB60DD9-41B9-4849-8DEE-D0F7432002CBQ41536252-90942D09-F577-4684-B06D-9010DBA37E00Q45711435-0B57CF89-70E2-456D-AB54-FF4FF12BC09EQ46178928-D4AE91D5-D433-4D81-A41E-3F0497CD657EQ47135290-54EE094E-664A-4E3B-9ADF-09941C6B57CEQ49641447-3CE87EE3-4D0C-42A6-93EF-9561C7D5F2ADQ50602624-4A2362D3-53D6-4386-9355-17B1E776539FQ51529844-34574800-47B8-4FAD-B174-AE12D13C9969Q51570037-8D82C117-378F-46B4-8276-5C1D03E31D0AQ55229995-0C826199-903C-4BBF-9910-53797AB529FAQ55515544-781D0A7D-83AA-4C04-B8A7-6D9BF713654B
P2860
Systemic inflammatory biomarkers and co-morbidities of chronic obstructive pulmonary disease.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Systemic inflammatory biomarke ...... obstructive pulmonary disease.
@en
type
label
Systemic inflammatory biomarke ...... obstructive pulmonary disease.
@en
prefLabel
Systemic inflammatory biomarke ...... obstructive pulmonary disease.
@en
P2860
P921
P1433
P1476
Systemic inflammatory biomarke ...... obstructive pulmonary disease.
@en
P2860
P304
P356
10.3109/07853890.2012.732703
P407
P577
2012-10-30T00:00:00Z